Rucaparib is a targeted therapy drug that targets specific gene mutations and is widely used in the treatment of ovarian and prostate cancer. This article will systematically sort out the core information that patients need to pay attention to from three aspects: medication guidance, dietary contraindications and indications, so as to help patients and their families better understand the rational use and precautions of drugs.

Guidelines for the administration of Rucaparib

The standardized use of Rucaparib directly affects the therapeutic efficacy and safety. Correct understanding of dosage, storage methods and adverse reaction management strategies is the key to maintaining efficacy.

Recommended dosage and administration

The standard dose of Rucaparib is 600 mg (two 300 mg tablets) orally twice daily for a total daily dose of 1200 mg. There is no need to consider eating when taking it, but it is necessary to take the medicine at a fixed time. If the dose is missed or vomited, the patient should not take the next dose and should continue the next dose as originally planned. Patients with metastatic castration-resistant prostate cancer require concomitant treatment with GnRH analogues or bilateral orchiectomy.

Storage conditions and expiration date

The drug should be stored in a dark and sealed environment at 20°C to 25°C, and the allowable temperature fluctuation range is 15°C to 30°C for short periods. Avoid moisture, direct sunlight and extreme temperatures. The original packaging should remain sealed after opening, and the integrity of the packaging should be checked regularly. The drug is valid for 24 months, and if it expires or the packaging is damaged, you need to stop using it immediately and consult a professional.

Rational medication and proper storage can maintain the stability of the drug to the greatest extent, and patients should strictly follow the doctor's instructions, regularly monitor liver function and blood indicators, and adjust the treatment plan in time.

Foods contraindicated in Rucaparib patients

Drug-diet interactions may affect efficacy or increase the risk of adverse effects, and patients should be especially aware of potential interferences with their daily diet.

Medications to avoid with natural ingredients

There is a clear interaction between Rucaparib and the CYP enzyme system to metabolize drugs. For example, amiodarone (CYP1A2 inhibitor), rifampicin (CYP3A inducer), ginkgo biloba (CYP2C9 substrate), and omeprazole (CYP2C19 inhibitor) may alter drug metabolism, resulting in abnormally high or low blood levels. If a combination is necessary, the dose should be adjusted according to the doctor's recommendation.

Dietary contraindications and precautions

Foods containing St. John's wort, grapefruit and their products should be avoided while taking Rucaparib, which may interfere with drug metabolism by affecting CYP3A4 enzyme activity. In addition, patients taking warfarin for a long time should have their coagulation monitored closely and the anticoagulant dose adjusted if necessary. Patients are advised to maintain a light diet and reduce the intake of high-fat foods during treatment to reduce the burden on the gastrointestinal tract.

By avoiding certain foods and drugs, patients can reduce the probability of adverse reactions and determine the safety of the treatment process.

Indications for Rucaparib

The clinical application of Rucaparib is based on precise molecular targets and is suitable for the treatment of malignant tumors caused by specific gene mutations.

Applicable disease and target mechanisms

The drug is mainly used for the maintenance treatment of recurrent ovarian cancer with BRCA gene mutations, and for metastatic castration-resistant prostate cancer with BRCA mutations. Its targets are PARP1, PARP2 and PARP3 enzymes, which selectively kill cancer cells carrying homologous recombination defects by inhibiting the DNA repair pathway of tumor cells.

Patient screening and efficacy evaluation

BRCA mutation status should be confirmed by genetic testing prior to treatment, and only mutation-positive patients may benefit from treatment. Regular imaging and tumor marker monitoring are required during treatment to assess disease progression. If intolerable toxicity occurs or the condition worsens, the regimen should be adjusted or the drug should be discontinued.

Identifying indications and targeting mechanisms can help optimize patient selection, provide a scientific basis for individualized treatment, prolong survival, and improve quality of life.